Get the Stockscreener App
28.11
2.23%
-0.64
After Hours:
28.12
0.01
+0.04%
Terns Pharmaceuticals Inc stock is traded at $28.11, with a volume of 1.03M.
It is down -2.23% in the last 24 hours and up +227.24% over the past month.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
See More
Previous Close:
$28.75
Open:
$28.99
24h Volume:
1.03M
Relative Volume:
0.39
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-95.90M
P/E Ratio:
-21.30
EPS:
-1.32
Net Cash Flow:
$-79.09M
1W Performance:
+6.82%
1M Performance:
+227.24%
6M Performance:
+818.63%
1Y Performance:
+343.38%
1-Day Range:
$28.11
$29.00
1-Week Range:
$26.13
$29.51
52-Week Range:
$1.865
$29.51
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Name
Terns Pharmaceuticals Inc
Sector
Industry
Phone
650-525-5535 EXT.101
Address
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
28.11 | 2.59B | 0 | -95.90M | -79.09M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.61 | 109.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.19 | 82.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.23 | 58.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
911.98 | 56.50B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.77 | 43.62B | 447.02M | -1.18B | -906.14M | -6.1812 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-03-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-04-25 | Resumed | H.C. Wainwright | Neutral |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Oct-31-24 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Mizuho | Buy |
| Jun-07-23 | Initiated | Jefferies | Buy |
| May-31-23 | Initiated | ROTH MKM | Buy |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-14-23 | Initiated | JMP Securities | Mkt Outperform |
| Feb-07-23 | Initiated | UBS | Buy |
| Sep-12-22 | Initiated | H.C. Wainwright | Neutral |
| Sep-14-21 | Resumed | Goldman | Buy |
| Mar-02-21 | Initiated | Cowen | Outperform |
| Mar-02-21 | Initiated | Goldman | Buy |
| Mar-02-21 | Initiated | JP Morgan | Overweight |
View All
Terns Pharmaceuticals Inc Stock (TERN) Latest News
Mizuho maintains Outperform rating on Terns Pharmaceuticals stock ahead of ASH data - Investing.com Canada
Broadcom To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Terns Pharmaceuticals stock price target raised to $35 from $25 at Citizens - Investing.com Canada
Terns Pharma (TERN) Price Target Raised by Citizens to $35 | TER - GuruFocus
Terns Pharmaceuticals (TERN) Is Up 6.5% After Positive TERN-701 Data at Jefferies Conference – Has the Bull Case Changed? - Sahm
Barclays Raises Price Target for Terns Pharma (TERN) to $36.00 | - GuruFocus
Terns falls as phase 2 data on oral GLP-1 obesity asset disappoints - MSN
BMO Believes Market Undervalues Terns Pharmaceuticals (TERN) Despite Strong Trial Data - MSN
What drives Terns Pharmaceuticals Inc stock priceEarnings Volatility Patterns & Explosive Profit Growth - earlytimes.in
10 Hottest SMID-Cap Stocks So Far In 2025 - Insider Monkey
First Week of July 2026 Options Trading For Terns Pharmaceuticals (TERN) - Nasdaq
Applying Wyckoff theory to Terns Pharmaceuticals Inc. stock2025 Buyback Activity & Expert Curated Trade Setup Alerts - newser.com
Is Terns Pharmaceuticals Inc. stock cheap at current valuationAnalyst Downgrade & Risk Controlled Daily Plans - newser.com
Is Terns Pharmaceuticals Inc. stock a top momentum playJuly 2025 Fed Impact & Weekly Setup with ROI Potential - newser.com
How hedge fund analytics apply to Terns Pharmaceuticals Inc. stock2025 Institutional Moves & Short-Term Trading Alerts - newser.com
Advanced analytics toolkit walkthrough for Terns Pharmaceuticals Inc.Market Rally & AI Driven Price Predictions - newser.com
Is Terns Pharmaceuticals Inc. still worth holding after the dipQuarterly Profit Report & AI Based Buy/Sell Signal Reports - newser.com
What Wall Street predicts for Terns Pharmaceuticals Inc. stock priceJuly 2025 Movers & Smart Swing Trading Techniques - newser.com
How sentiment analysis helps forecast Terns Pharmaceuticals Inc.Long Setup & AI Enhanced Market Trend Forecasts - newser.com
Terns Pharma (TERN) Sees Target Price Raised by Truist Securitie - GuruFocus
Truist Securities raises Terns Pharmaceuticals stock price target to $35 on positive ASH data - Investing.com Canada
Terns Pharmaceuticals stock hits 52-week high at 27.8 USD By Investing.com - Investing.com Nigeria
Terns Pharmaceuticals stock hits 52-week high at 27.8 USD - Investing.com
Truist Raises Price Target on Terns Pharmaceuticals to $35 From $28, Keeps Buy Rating - MarketScreener
How Terns Pharmaceuticals Inc. stock reacts to Fed rate cutsWeekly Risk Summary & Reliable Intraday Trade Alerts - newser.com
Relative strength of Terns Pharmaceuticals Inc. in sector analysis2025 Market Outlook & Growth Focused Investment Plans - newser.com
From Olema To Insmed: Are These High-Flying Biotechs Still Worth Buying? - RTTNews
Could Positive Early Data for TERN-701 Shift Terns Pharmaceuticals' (TERN) Long-Term Competitive Position? - Yahoo Finance
BMO Capital Maintains Terns Pharmaceuticals (TERN) Outperform Recommendation - Nasdaq
Terns Pharma (TERN) Sees Rating Maintained but Price Target Rais - GuruFocus
Commit To Buy Terns Pharmaceuticals At $20, Earn 36.5% Annualized Using Options - Nasdaq
Could Terns Pharmaceuticals' (TERN) Increased Conference Visibility Reflect a Shift in Management Strategy? - Sahm
Terns Pharmaceuticals (TERN) Soars to New Record High of $26.12 - Finviz
10 Firms Shining Bright in a Bleeding Market - Insider Monkey
TERN: 64% response in refractory CML and strong safety drive rapid pivotal trial plans - TradingView
William Blair Reiterates a Buy on Terns Pharmaceuticals (TERN) - MSN
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday - Benzinga
Terns Pharmaceuticals (TERN) Price Target Increased by 65.68% to 26.75 - Nasdaq
Will Terns Pharmaceuticals Inc. stock recover after recent dropTrade Risk Summary & Technical Pattern Based Signals - newser.com
10 Hottest Small Cap Stocks to Buy Now - Insider Monkey
Terns Pharmaceuticals Inc Stock (TERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):